Temporal trends in patient characteristics and outcomes among children enrolled in Mozambique's national antiretroviral therapy program

Pediatric Infectious Disease Journal

Volumn 34, Issue 8, 2015, Pages e191-e199

  Auld, Andrew F ^a   Alfredo, Charity ^b   Macassa, Eugenia ^c   Jobarteh, Kebba ^b   Shiraishi, Ray W ^a   Rivadeneira, Emilia D ^a   Houston, James ^a   Spira, Thomas J ^a   Ellerbrock, Tedd V ^a   Vaz, Paula ^d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Ministerio da Saude   (Mozambique)

^d Fundaco Ariel Glaser Contra O SIDA Pediátrico Ariel   (Mozambique)

Author keywords

Mozambique; pediatric antiretroviral therapy; treatment outcomes

Indexed keywords

ALANINE AMINOTRANSFERASE; EFAVIRENZ; HEMOGLOBIN; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ADOLESCENT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY HEIGHT; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CHILDHOOD MORTALITY; FEMALE; FOLLOW UP; GENDER; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MOZAMBIQUE; NEWBORN; PATIENT MONITORING; PATIENT REFERRAL; PNEUMONIA; PREDICTOR VARIABLE; PRIORITY JOURNAL; TEMPORAL ANALYSIS; TREATMENT OUTCOME; TREND STUDY; TUBERCULOSIS; HIV INFECTIONS; MORTALITY; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; LOST TO FOLLOW-UP; MALE; MOZAMBIQUE; RETROSPECTIVE STUDIES;

EID: 84937429791     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000741     Document Type: Article

References (42)

1. United Nations Childrens Fund. HIV/AIDS and children. Available at: http://www.unicef.org/mozambique/hiv-Aids-2967.html. Accessed January 1, 2014
2. Newell ML, Coovadia H, Cortina-Borja M, et al; Ghent International AIDS Society (IAS) Working Group on HIV Infection in Women and Children. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364: 1236-1243
3. Prendergast AJ, Penazzato M, Cotton M, et al. Treatment of young children with HIV infection: using evidence to inform policymakers. PLoS Med. 2012; 9: e1001273
4. Global report: UNAIDS report on the ENGLglobal AIDS epidemic 2013 http://www.unaids.0org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf United Nations Programme on HIV/AIDS Available at Accessed February 17, 2014
5. Cornell M, Grimsrud A, Fairall L, et al; International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 2010; 24: 2263-2270
6. Auld AF, Mbofana F, Shiraishi RW, et al. Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One. 2011; 6: e18453
7. Leroy V, Malateste K, Rabie H, et al; International IeDEA Pediatric Working Group1. Outcomes of antiretroviral therapy in children in Asia and Africa: a comparative analysis of the IeDEA pediatric multiregional collaboration. J Acquir Immune Defic Syndr. 2013; 62: 208-219
8. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants: Recommendations for a public health approach, 2010 revision. Available at: http://whqlibdoc.who. int/publications/2010/9789241599818-eng.pdf. Accessed February 17, 2014
9. Ciaranello AL, Chang Y, Margulis AV, et al. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-Analysis. Clin Infect Dis. 2009; 49: 1915-1927
10. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants in Resource-Limited Settings-Towards Universal Access: Recommendations for a Public Health Approach, 2006 Version. Geneva, Switzerland: WHO; 2006. http://www. who.int/hiv/pub/guidelines/WHOPMTCT.pdf. Accessed August 9, 2010
11. Royston P. Multiple imputation of missing values: update of ice. Stata J. 2005; 5: 527-536
12. White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med. 2009; 28: 1982-1998
13. Schöni-Affolter F, Keiser O, Mwango A, et al; Swiss HIV Cohort Study; IeDEA Southern Africa. Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland. PLoS One. 2011; 6: e27919
14. Brentlinger PE, Torres JV, Martínez PM, et al. Clinical staging of HIVrelated illness in Mozambique: performance of nonphysician clinicians based on direct observation of clinical care and implications for health worker training. J Acquir Immune Defic Syndr. 2010; 55: 351-355
15. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515-526
16. Royston P, Carlin JB, White IR. Multiple imputation of missing values: new features for mim. Stata J. 2009; 9: 252-264
17. Violari A, Cotton MF, Gibb DM, et al; CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008; 359: 2233-2244
18. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access-recommendations for a public health approach-2010 revision. Available at: http://whqlibdoc.who. int/publications/2010/9789241599801-eng.pdf. Accessed April 30, 2014
19. Lowenthal ED, Ellenberg JH, Machine E, et al. Association between efavirenz- based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children. JAMA 2013; 309: 1803-1809
20. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010; 363: 1510-1520
21. Lallemant M, Chang S, Cohen R, et al. Pediatric HIV-A neglected disease?. N Engl J Med. 2011; 365: 581-583
22. Bakeera-Kitaka S, Fillekes Q, Keishanyu R, et al. Pharmacokinetics and acceptability of a new generic lopinavir/ritonavir sprinkle formulation in African, HIV+ children 1-4 years: CHAPAS-2 (Poster # 975b). In: Conference on Retroviruses and Opportunistic Infections (CROI), 20th Conference; March 3-6, 2013, Atlanta, USA. Available at: http://www.dndina.org/component/content/article/2-events/104. Accessed April 30, 2014
23. Fatti G, Bock P, Eley B, et al. Temporal trends in baseline characteristics and treatment outcomes of children starting antiretroviral treatment: an analysis in four provinces in South Africa, 2004-2009. J Acquir Immune Defic Syndr. 2011; 58: e60-67
24. McNairy ML, Lamb MR, Carter RJ, et al; Identifying Optimal Models of HIV Care and Treatment in Sub-Saharan Africa Consortium. Retention of HIV-infected children on antiretroviral treatment in HIV care and treatment programs in Kenya, Mozambique, Rwanda, and Tanzania. J Acquir Immune Defic Syndr. 2013; 62: e70-e81
25. Decroo T, Panunzi I, das Dores C, et al. Lessons learned during down referral of antiretroviral treatment in Tete, Mozambique. J Int AIDS Soc. 2009; 12: 6
26. United Nations Office for the Coordination of Humanitarian Affairs. Mozambique: closing HIV day care centres brings protesters out. Available at: http://www.irinnews.org/report/85587/mozambique-closing-hiv-daycare- centres-brings-protesters-out. Accessed December 31, 2013 United Nations Office for the Coordination of Humanitarian Affairs
27. Forster M, Bailey C, Brinkhof MW, et al; ART-LINC collaboration of International Epidemiological Databases to Evaluate AIDS. Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. Bull World Health Organ. 2008; 86: 939-947
28. World Health Organization. WHO country cooperation strategy: 2009-2013. Available at: http://www.who.int/countryfocus/cooperation- strategy/ccs-moz-en.pdf. Accessed December 30, 2013
29. Musheke M, Bond V, Merten S. Individual and contextual factors influencing patient attrition from antiretroviral therapy care in an urban community of Lusaka, Zambia. J Int AIDS Soc. 2012; 15 (Suppl 1): 1-9
30. UNDP. Human development index, 2012. Available: https://data.undp.org/dataset/Table-1-Human-Development-Index-And-its-components/wxubqc5k. Accessed December 30, 2013
31. Decroo T, Telfer B, Biot M, et al. Distribution of antiretroviral treatment through self-forming groups of patients in Tete Province, Mozambique. J Acquir Immune Defic Syndr. 2011; 56: e39-e44
32. Koole O, Tsui S, Wabwire-Mangen F, et al. Retention and risk factors for attrition among adults in antiretroviral treatment programmes in Tanzania, Uganda and Zambia. Trop Med Int Health. 2014; 19: 1397-1410
33. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007; 298: 1888-1899
34. Miller TL. Nutritional aspects of HIV-infected children receiving highly active antiretroviral therapy. AIDS 2003; 17 (Suppl 1): S130-S140
35. Ansari NA, Kombe AH, Kenyon TA, et al. Pathology and causes of death in a series of human immunodeficiency virus-positive and -negative pediatric referral hospital admissions in Botswana. Pediatr Infect Dis J. 2003; 22: 43-47
36. World Health Organization. Guidelines for an integrated approach to the nutritional care of HIV-infected children (6 months-14 years). Available at: http://whqlibdoc.who.int/publications/2009/9789241597524-eng-Handbook. pdf. Accessed January 7, 2014
37. Nicol MP, Workman L, Isaacs W, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis. 2011; 11: 819-824
38. Gil AC, Lorenzetti R, Mendes GB, et al. Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy. Sao Paulo Med J. 2007; 125: 205-209
39. Pol S, Lebray P, Vallet-Pichard A. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis. 2004; 38 (Suppl 2): S65-S72
40. Taha TE, Kumwenda N, Gibbons A, et al. Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants. AIDS 2002; 16: 851-858
41. Anigilaje EA, Olutola A. Prevalence and clinical and immunoviralogical profile of human immunodeficiency virus-hepatitis b coinfection among children in an antiretroviral therapy programme in Benue State, Nigeria. ISRN Pediatr. 2013; 2013: 932697
42. Geng EH, Emenyonu N, Bwana MB, et al. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA 2008; 300: 506-507